ClinicalTrials.gg
CompletedNCT02549196CPC-12Updated Mar 5, 2019Results posted

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

A Phase 2 interventional study of Donepezil and Solifenacin in Dementia of Alzheimer's Type, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan plc. Completed at 4 sites in United States. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2019-03-05.

Sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan plc (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
50 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing donepezil in Dementia — none open to participants now, none under way, none of them phase 3. Donepezil · Dementia.

Enrollment
22nd of 24
28 · median 151
Started
2015
with 3 others
Phase 2
5 of 26
none open now
Registered
24th of 26
by date
Lead sponsor
1 of 26
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc

Among the 26 studies testing donepezil in Dementia, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2015, is one of 5 in phase 2, and was the 24th registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 573 are open to participants now.

Browse Dementia studies →

Open to participants now

None of the 26 studies testing donepezil in Dementia is open now. The open studies under Dementia, anywhere →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 50 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing donepezil in Dementia as a file.
02

Study summary

This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.

Read the detailed description

This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule. The study involves a step wise cohort design in two different patient populations: Group 1 will comprise of patients who have been treated with low dose of CPC-201(5 or 10 mg/day) (given once daily) for at least 4 weeks just prior to Day1. Group 2 will consist of patients who have never been treated with CPC-201 before or who have not received any other AChEI for the past 6 months.

In this study, CPC-201 dose will be increased at weekly intervals, in accordance with the schedules given below, to its first intolerable dose (FID) or maximum allowed dose (MAD) of 60 mg/day (40mg/day for Cohort 3c) together with solifenacin 15 mg/day.

Cohort 1 1st week: 20mg 2nd week: 30mg 3rd week: 40mg 4th week: 50mg 5th week: 60mg Cohort 2* 1st week: 20mg 2nd week: 40mg 3rd week: 60mg Cohort 1b 1st - 2nd week: 10mg 3rd week: 20mg 4th week: 30mg 5th week: 40mg 6th week: 50mg 7th week: 60mg Cohort 3c* 1st week: 10mg 2nd week: 15mg 3rd week: 20mg 4th week: 25mg 5th week: 30mg 6th week: 35mg 7th week: 40mg

*: The dose titration schedule of Cohort 2 and 3 may be altered based on Cohort 1 result.

Patients will be enrolled in Cohort 2 only when patients enrolled in Cohort 1 have safely completed titration. Similary, patients will be enrolled in Cohort 3, only when patients enrolled in Cohort 2 have safely completed titration.

Patients reaching their FID or having completed one week treatment with donepezil 40mg/day, have two options.

Option 1: Patient will be allowed to immediately enter a long term extension at their Maximum tolerated dose (MTD) or MAD.

Option 2: Patients may choose not to enter the long term extension, in which case the Investigator will decide whether the patient should discontinue high dose of donepezil without down-titration, or whether donepezil should be downtitrated to their own standard of donepezil dose.

03

Conditions studied

  • Dementia of Alzheimer's Type

Browse trials for

04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed an Institutional Review Board (IRB) approved document
  2. Aged 50 - 89 years inclusive.
  3. Meeting the diagnosis of probable AD consistent with:

    • Revised National Institute on Aging-Alzheimer's Disease Association (NIA-ADA) criteria and
    • (DSM IV) criteria.
  4. Mild to severe severity (Mini-Mental Status Exam [] scores 7 - 24 inclusive).
  5. Rosen-Modified Hachinski Ischemia Score of ≤4.
  6. Have a suitable caregiver to supervise the at-home administration of study drugs and observe for AEs.
  7. Patients treated with donepezil 5 or 10 mg/day (given once daily) for at least 4 weeks just prior to Day1 for Population (group) 1 or;
  8. Patients never been treated with donepezil before (donepezil naïve) or who have not received any other AChEI for the past 6 months for Population (group) 2.
  9. Patients in generally good health as indicated by their medical history and physical examination, vital signs, (ECG), and standard laboratory tests.

Exclusion criteria

Exclusion Criteria:

  1. Women of child bearing potential.
  2. History or presence of a seizure disorder.
  3. Current unstable peptic ulcer disease, urinary or gastric retention; asthma or obstructive pulmonary disease.
  4. History or presence of bladder outflow obstruction, gastrointestinal obstructive disorder or reduced GI motility, or narrow-angle glaucoma.
  5. History or presence of gastrointestinal, hepatic, or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  6. Renal and hepatic dysfunction with:

    • Total : >1.5 x UNL
    • : >2.5 x UNL
    • ALT: >2.5 x UNL
    • Serum Creatinine: >1.5 x UNL
    • : \<30 mL/min (calculated by Cockcroft and Gault equation)
  7. History or presence of myasthenia.
  8. History or family history of Prolonged Syndrome.
  9. History of unexplained syncope or family history of unexplained syncope or sudden death.
  10. Myocardial infarction or hospitalization for congestive heart failure within 6 months.
  11. findings of:

    • Complete Left Bundle Branch Block;
    • Ventricular pacing;
    • 2nd degree or 3rd degree AV block;
    • Atrial fibrillation or atrial flutter;
    • HR \<45 or >100;
    • PR >220 msec; or
    • QTcF >450 msec in male, >470 msec in female
  12. Known to donepezil, solifenacin or related drugs.
  13. History of drug significant allergy.
  14. History of substance abuse, known drug addiction, or positive test for drugs of abuse or alcohol.
  15. Patients treated with the following medications within 8 weeks of screening

    • AChEIs (other than donepezil),
    • Peripherally acting anticholinergics (such as drugs for the treatment of overactive bladder disorder),
    • Psychoactive medications (including antipsychotics, antidepressants, anxiolytics or sedative hypnotics) having significant anticholinergic effects and/or believed to affect cognitive function.

    Other medications are acceptable, at the investigators discretion, if dosage is held stable for at least 4 weeks prior to screening and throughout the study.

  16. Patients considered unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator.
  17. Patients hospitalized within 4 weeks of screening.
  18. Any other acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives.
  19. Patients who have participated in another clinical trial with an drug within previous 30 days.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.

    Drug: Donepezil · Drug: Solifenacin

  • Experimental
    Cohort 2

    Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.

    Drug: Donepezil · Drug: Solifenacin

  • Experimental
    Cohort 1b

    Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.

    Drug: Donepezil · Drug: Solifenacin

  • Experimental
    Cohort 3c

    Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.

    Drug: Donepezil · Drug: Solifenacin

Interventions

  • Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

  • Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort

    Of the four cohorts with different dosing schedules for CPC-201, the cohort with the greatest proportion of participants to reach the donepezil MAD was determined to be the optimal administration regimen.

    Time frame: 1-7 weeks

Secondary outcomes

  1. Number of Participants With TEAEs Leading to Study Drug Discontinuation

    Number of subjects who experienced any treatment-emergent adverse events (TEAEs) leading to study drug discontinuation

    Time frame: 1-7 weeks

07

Results

Posted Mar 5, 2019

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 1bCohort 3c
Started81613
Completed71512
Not completed1011
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject1010

Outcome measures

PrimaryNumber of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort

Of the four cohorts with different dosing schedules for CPC-201, the cohort with the greatest proportion of participants to reach the donepezil MAD was determined to be the optimal administration regimen.

Time frame:
1-7 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort
ParticipantsCohort 1Cohort 2Cohort 1bCohort 3c
Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort2016
SecondaryNumber of Participants With TEAEs Leading to Study Drug Discontinuation

Number of subjects who experienced any treatment-emergent adverse events (TEAEs) leading to study drug discontinuation

Time frame:
1-7 weeks
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Study Drug Discontinuation
ParticipantsCohort 1Cohort 2Cohort 1bCohort 3c
Number of Participants With TEAEs Leading to Study Drug Discontinuation2014

Adverse events

Collected over Adverse events were collected until week 7.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/8 (0%)1/8 (12.5%)6/8 (75%)
Cohort 20/1 (0%)0/1 (0%)1/1 (100%)
Cohort 1b0/6 (0%)0/6 (0%)6/6 (100%)
Cohort 3c1/13 (7.7%)1/13 (7.7%)12/13 (92.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2Cohort 1bCohort 3c
SyncopeNervous system disorders1/80/10/60/13
Duodenal ulcer haemorrhageGastrointestinal disorders0/80/10/61/13
Cardio-respiratory arrestCardiac disorders0/80/10/61/13
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCohort 1Cohort 2Cohort 1bCohort 3c
NauseaGastrointestinal disorders4/81/12/62/13
VomitingGastrointestinal disorders4/80/11/62/13
DizzinessNervous system disorders2/80/12/61/13
Abdominal pain upperGastrointestinal disorders2/80/10/60/13
HeadacheNervous system disorders2/80/10/60/13
ConstipationGastrointestinal disorders1/80/10/63/13
Blood pressure systolic increasedInvestigations0/80/10/63/13
Decreased appetiteMetabolism and nutrition disorders0/80/11/63/13
TremorNervous system disorders1/80/11/61/13
AnxietyPsychiatric disorders0/80/11/61/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Cohort 1bCohort 3cTotal
Mean72 ± 10.67475.5 ± 6.973 ± 8.473.3 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 1bCohort 3cTotal
Female603514
Male213814
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Cohort 1bCohort 3cTotal
White8151125
Black or African- American00123
08

Study locations

4 sites
  • Quantum Laboratories
    Deerfield Beach, Florida 33064, United States
  • Miami Jewish Health Systems
    Miami, Florida 33137, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • PMG Research
    Winston-Salem, North Carolina 27103, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Sep 2017, 23 months.

Results were first posted in Mar 2019, 1 year 5 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Dementia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 23 months is below that.

Counting every sponsor, half of 83 studies reached it within 38 months; a quarter within 23 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2015
First posted
Sep 15, 2015
StartActual
Oct 7, 2015
Primary completionActual
Sep 28, 2017
CompletionActual
Sep 28, 2017
Results first posted
Mar 5, 2019
Last update
Mar 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02549196
Responsible party
Sponsor
First posted
Sep 15, 2015
Start date
Oct 7, 2015
Primary completion
Sep 28, 2017
Completion
Sep 28, 2017
Results posted
Mar 5, 2019
Last update
Mar 5, 2019

Study contacts

Lynn James
study chair · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Donepezil · Solifenacin

Start the discussion